CD4 and hepatocellular carcinoma: In conclusion, this is the first study to construct and assess a novel nomogram based on quantitative CEMR parameters in combination with peripheral CD4+ lymphocyte subpopulations to identify HCC patients who might benefit from combined systemic treatment of anti-angiogenesis and ICI.